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As nested case-control (NCC) design is becoming more popularly used in 
epidemiological and genetic studies, the need of methods that allows the re-use of 
NCC data is greater than ever. However, due to the incidence density sampling, 
re-using data from NCC studies for analysis of secondary outcomes is not 
straightforward. Several recent methodological developments have opened the 
possibility for prior NCC data to be used as complement controls in a current study 
thereby improving study efficiency. However, practical guidelines on the effectiveness 
of prior data relative to newly sampled subjects and the potential power gains are still 
lacking.  
Objective: 
The goal of this thesis is to investigate how the precision of the variance estimates of 
the hazard ratios varies with the study size and number of controls per case when we 
re-use prior nested case-control (NCC) data to supplement a new NCC study in 
different simulation settings, such as different levels of overlaps in matching variables. 
We want to demonstrate the feasibility and efficiency of conducting a new study using 
only incident cases and prior data and to apply the method to two different sets of real 
data. In addition, we would like to give some practical guidance regarding the 




We simulate the study data of one prior and one current or new NCC studies in the 
same cohort and estimate hazard ratios using weighted log-likelihood with the weight 
given by the inverse of the probability of inclusion in either study. We also express the 
contribution of prior controls to the new study in terms of “effective number of 
controls”. Based on this effective number of controls idea, we show how researchers 
can assess the potential power gains from re-using prior NCC data. We apply the 
method to analyses of anorexia and contra-lateral breast cancer in the Swedish 
population and show how power calculations can be done using publicly available 
software. 
Results and Conclusion: 
We have demonstrated the feasibility of conducting a new study using only incident 
cases and prior data. The combined analysis of new and prior data gives unbiased 
estimates of hazard ratio, with efficiency depending on study size and number of 
controls per case in the prior study. We have also investigated in detail the impact of 
the number of controls per case in the prior and current studies on the relative 
efficiency when re-using prior subjects in a nested case-control study. For a fixed 
number of controls in the prior study, the relative reduction in the variance decreases 
as we increase the number of controls in the new study. The ability to re-use NCC 
data offers researchers several cost-saving strategies when designing a new study. 
This work has important applications in all areas of epidemiology but especially in 
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Chapter 1 Introduction 
1.1 Study Design for Epidemiological studies 
To study risk factors of a disease, epidemiologist can choose from an array of study 
designs. With different study designs offer comparative advantages in different 
situations. Cohort studies as a form of longitudinal observational study are widely 
used in medicine, as well as in social science (called longitudinal or panel study [1]), 
actuarial science [2] and ecology [3]. Researchers recruit a group of healthy 
individuals at baseline, and then follow them up by recording their disease outcomes 
and exposure patterns overtime. Risk factors are usually identified by calculating the 
relative risk i.e. the ratio of disease incidence in subjects exposed to certain risk 
factors against those unexposed. Compared to other study designs (such as 
cross-sectional and case-control designs), cohort studies allow researchers to study 
multiple outcomes, but require relatively large sample size and also need to be 
followed up for a long time as most diseases affect only a small proportion of a 
population, which leads to substantial amount of time and cost investment.  
If researchers intend to provide more timely results using a cohort design, at first 
increasing the size of the cohort seems to be the way out. But this will result in further 
cost in maintaining the cohort which may not be realistic. A simpler way to save time 
and money is to use a case-control design instead, which is particularly useful in 
studying rare conditions with very long latency. A case-control study gathers cases 
with the defined outcome disease together with (matched) controls without the 
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condition, and then retrospectively collects exposure information that might have 
caused the disease/condition. In a case-control design, the odds ratio of exposure can 
be used to estimate the relative risk using logistic model when the outcome of interest 
is rare. Case-control studies can yield important scientific findings with relatively 
little time and cost investment compared with other study designs (such as cohort 
design and randomized control trials). Unfortunately, they tend to be more susceptible 
to biases than cohort studies [4, 5].  
To minimize cost and time investments while maintaining positive features of cohort 
studies (e.g., robustness against recall biases), some study designs that employ 
case-control selection within cohort studies have been proposed. Case-cohort and 
nested case-control (NCC) studies [6, 7] are the two most commonly used designs 
from this class of designs, which are good examples of cost-efficient designs where 
exposure information is collected for all cases but only a fraction of controls in the 
whole cohort, while still preserving most of the study power when compared to a full 
cohort study.  
The case-cohort design was first proposed for large survey studies such as the 
Women’s Health Study by Prentice [6]. The covariate information is collected for all 
cases in the whole cohort at their failure time; the researchers randomly select a 
subcohort from the original cohort of interest at entry and also collect covariate 
information on a follow-up basis for the chosen cohort. Binder [8] gave general 
results for Cox proportional hazards models and survey sampling designs in this 
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design. Therneau and Li [9] described how to obtain estimates for risk factors and 
corresponding variances using proportional hazards regression. 
In comparison, NCC design suggested by Thomas [10] samples controls at each event 
time from the population still at risk, and the controls are highly likely to be matched 
to certain characteristics of the case. Under a proportional hazard model, the effect 
estimates can be obtained by maximizing a Cox-type likelihood, which later being 
proved as a partial likelihood by Oakes [11]. 
1.2 Ideas for re-using existing data 
Considering today’s epidemiological studies scale, even the most time and 
cost-saving design such as case-control study requires a substantial amount of effort 
and money. Once the analysis is finished, most investigators would like to move on to 
study some additional factors in the original study. This is constrained by the nature 
or limitation of the study design. For example, data from case-control studies can only 
be used to investigate the primary outcome [12, 13]. This is because the sampling of 
subjects in a case-control design is not totally random, as it is designed to over-sample 
the subjects with the disease of interest. At the same time, the controls are most likely 
to be matched to cases on important confounding variables. Then the subjects are not 
representatives of the study population and the estimates will be biased if 
investigators just apply standard statistical methods to analyze a new outcome. As the 
existing data has great potential for researchers, the ability to re-use the existing data 
is often desired.  
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1.3 Re-using existing case-control data 
Various studies have been conducted to study the re-using or re-analysing previous 
case-control studies. Nagelkerke et al. [14] addressed the validity of secondary 
analysis which concerns the relationship among the covariates rather than the disease 
outcome and covariates. The authors summarized some very restrictive situations 
when no bias occurred using conventional logistic regression, such as when the 
secondary response variable and the case-control outcome variable are conditionally 
independent given the covariates, the ordinary logistic regression will be appropriate. 
Otherwise if the case-control variable and the covariates are conditionally 
independent given the secondary response variable, then the regression coefficients 
will be valid except for the constant term. These conditions are not easily satisfied 
though for most of the studies. The authors concluded that in most situations, it is 
valid to regress one covariate as the secondary outcome on others in the original 
control group given that the controls are representatives of the non-diseased 
population, but not in the cases or the combined sample. But this may result in 
discarding as much as half of the data, identifying risk factors becomes more difficult 
with the loss of power and efficiency. 
Lee et al. [15] discussed how to calculate maximum likelihood estimates of all the 
regression coefficients in a less restrictive condition, compared to that described by 
Nagelkerke et al. [14]. In the situation where a variable that was a covariate in the 
original study now become the response variable, the restrictive conditions required 
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only knowing the sampling rates for cases and controls and the original case-control 
status variable is not itself a covariate in the secondary study. The authors modified 
the Scott-Wild method [16] and estimated the conditional distribution of the 
secondary response given the covariates by estimating the joint distribution of the 
stratifying case-control variable and the secondary response variable. After fitting the 
joint model, the marginal distribution will then give the desired conditional 
distribution. 
Reilly et al. [17] presented a simple approach to the analysis for the situation where a 
covariate or exposure variable in the original case-control study now became the 
secondary response variable using an appropriately weighted regression model. The 
re-using of case-control data was treated as a two-stage design, where the first-stage is 
the underlying study population and the second-stage is the existing data. As the 
existing data could be viewed as a stratified random sample by the case-control status 
variable as well as other stratification variables, the sampling intensity is needed to 
compensate for biased sampling schemes and also construct an unbiased 
cross-sectional representation of the study population [18]. Weighted logistic 
regression was then showed to produce the same results as a more sophisticated 
analysis such as a pseudo-likelihood method which requires additional model 
assumptions and non-standard software tools. 
Jiang et al. [19] compared weighted likelihood and semi-parametric maximum 
likelihood methods. For the semi-parametric method, using the reasoning discussed 
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by Scott et al. [20] and Neuhaus et al. [21], the authors modeled the joint distribution 
of Y1 and Y2 given x in various ways, such as Palmgren [22] model and copula 
association [23] models, but always treated the covariate distribution g(x) 
nonparametrically where Y1 and Y2 are the two diseases of interest and x is the matrix 
of covariates. These two methods are both justified theoretically, while semi- 
parametric maximum likelihood method could be as much as twice as efficient as the 
weighted method but subject to bias when the nuisance models are mis-specified. 
Weighted likelihood method which takes the contributions to the score-equations for 
fitting a model to prospective data and weight them inversely to their probabilities of 
selection, is simple to implement and robust in the sense that there is no need to 
specify nuisance models. The authors concluded that the discussion does not lead to 
any easy answers for practitioners and suggested readers to always perform both 
analyses. It is worth noticing that when the estimates by the two methods differ, we 
should report the estimates from the weighted likelihood method as it needs no 
nuisance models and thus is more robust. 
These existing methods for re-using case-control data enable considerable savings in 
the budget for the study of the new outcome. These methods apply to simple 
case-control studies where sampling is stratified on outcome and various covariates, 
but they cannot be used for NCC study directly. As mentioned above, in a NCC study, 
a specified number of matched controls is selected from among those in the cohort 
who have not developed the disease by the time of diagnosis of the case. Because of 
the incidence density sampling, controls in the NCC study are not representative of 
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the underlying cohort: specifically, subjects with longer survival time (with respect to 
the disease) are more likely to be selected as controls. As a consequence of this, 
collected control information is not readily re-usable for analyzing a secondary 
outcome. 
1.4 Re-using existing nested case-control data 
Applying a conditional logistic regression on the NCC study provides valid estimates 
of the hazard ratios which can be obtained using a Cox regression on the whole cohort 
[24]. The NCC design shows potential reductions in the time and cost which provides 
comparable results to the whole cohort design, but has been limited to study a specific 
disease of interest as the controls are tied to their time-matched cases. 
Samuelsen [25] described that conditional inclusion probabilities of ever being 
included in the NCC study can be obtained, where the inclusion probabilities can be 
used in pseudo-likelihoods by weighting the individual log-likelihood contribution by 
their inverse. The author constructed the pseudo-likelihoods and derived the 
covariance matrices of the pseudo-scores and the expectations of the pseudo- 
information matrices. The asymptotic distributions of the pseudo-likelihood 
estimators as well as the variance estimators are also suggested. The possibility of 
using controls from a previous NCC selection in the analysis of other diseases was 
mentioned, but the idea was not studied further.  
When designing a new NCC study, it would be desirable to be able to utilize the 
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controls from a previous NCC study, instead of selecting new controls entirely, given 
that the covariates in the previous study are also relevant to the new study. It will be 
even better if the cases in the previous NCC study can also be utilized as controls for 
the new outcome of interest. The above paper makes it possible to fit parametric 
regression model and motivates our further efforts with the plentiful data stored in 
bio-banks as well as population-based registers. We will come back to the details in 
the subsequent chapters. 
Saarela et al. [26] reviewed current methods based on weighted partial or 
pseudo-likelihoods, while also proposed full likelihood-based parameter estimation. 
The authors formulated the problem of utilizing the previously selected control group 
in the framework of the competing risks survival model. The methods discussed are 
more related to the analysis of a case-cohort design, where the controls are not tied to 
the cases. It was stated that the likelihood-based approach gave slightly better 
efficiency compared with the weighted partial likelihood estimators, but it required 
modeling of the distribution of the partially observed covariate. 
Most recently, Salim et al. [27] demonstrated precision improvement by combining 
data from a small NCC study with data from a larger NCC study in the same or 
overlapping cohort. Using the inverse probability weighting concept, the individual 
log-likelihood contribution of each subject is weighted by the inverse of its inclusion 
probability. The authors conjectured that the efficiency gain depends on the number 
of cases with previous disease outcome relative to the number of cases with the 
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current disease of interest.  
We are also partly inspired by the huge amount of existing NCC data in many areas, 
such as Genome-wide association studies (GWAS) in genetic epidemiology as well as 
biomarker studies. GWAS and biomarker studies are used to identify common genetic 
factors or biomarkers that influence health and disease. For example, Han et al. [28] 
performed genotyping in a NCC study of postmenopausal invasive breast cancer 
within the Nurses’ Health Study (NHS) cohort to identify novel alleles associated with 
hair color and skin pigmentation using Illumina HumanHap550 array. Naveed et al. 
[29] conducted a NCC study to investigate if metabolic syndrome biomarkers are risk 
factors for loss of lung function after the famous 911 irritant exposure. 
1.5 Objectives 
The existing studies mentioned above with huge amount of information emphasize the 
needs and the importance of studying the re-using method. We want to look into the 
details of the impact of the number of controls per case in the prior and current studies 
on the relative efficiency when re-using prior subjects in a nested case-control study. 
Using both simulated and real data, our work complements recent theoretical 
developments, by providing practical guidelines for re-using prior nested case-control 
data and this should bring researchers a step closer to taking advantage of this 
possibility for more cost-effective studies. It will be very useful to applied statisticians, 
epidemiologists, and medical researchers interested in cost and budget savings when 
designing nested case-control studies.  
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1.6 Outline of thesis 
Chapter 2 and 3 describes our approaches for re-using NCC studies; the statistical 
model and the simulation procedure are discussed in details, followed by the 
simulation results. Simulated cohorts are used to examine the gain in efficiency from 
re-using nested case-control data, when the ’recycled’ data are used to supplement 
control information in a current study, including the special case where the current 
study samples only cases and relies on the prior data for control information. Chapter 
4 illustrates our approach using combined data sets from 2 NCC studies to investigate 
risk factors for anorexia nervosa in a cohort of young women in Sweden, in which we 
have underlying true estimates to compare with. We also give another illustration 
using combined data sets from one existing NCC study and one current NCC study 
which has not collected any control to investigate risk factors for developing 
contra-lateral breast cancer (CBC) in a cohort of Swedish breast cancer patients who 
have survived for 1 year since diagnosis. Chapter 5 summarizes our findings, 






Chapter 2: Re-using NCC data 
2.1 The cohort study 
To define a NCC study, first of all we need to define the study cohort where the NCC 
study is nested within. In our case, we will draw two independent NCC studies from 
the same study cohort described here. We assume the cohort consists of N individuals 
and the hazard functions of the two diseases (we denote the disease in the first study 
as A and the disease of interest in the current or second study as B) follow the Cox 
proportional hazards model: 
       (1) 
where t denotes the time on study (or equivalently calendar time), λ0k(t) is the 
baseline hazard for disease k (either A or B), Xik and Zik(t) are matrices of fixed 
(exposure and matching) covariates and time-dependent covariates for individual i 
(ranges from 1 to N), βk and γk are the regression parameters which describe the 
relationship between these covariates and the outcome k. 
We will denote the start of follow-up for individual i as si, the time to event (disease k 
onset or censoring time) as tik and the time to exit as ei in the following discussion.  
2.2 The two nested case-control studies 
The cohort is followed up prospectively with respect to occurrence of disease A and B 
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in our setting. We define a risk set Ri as the collection of individuals who share the 
same values of matching variables as the individual i who got the disease k at time tik, 
but still free of the disease. The earlier study randomly selects mA matched controls 
from the risk set, while the current study randomly selects mB matched controls from 
the risk set each time. By denoting Dk as the set of incident cases of disease k, Ri as 
the subset of selected individuals from the risk set Ri, valid estimates of θk = (βk, γk) 
can be obtained by maximizing the partial likelihood within each of the NCC studies. 
    (2) 
Our interest here is in re-using prior data from the prior study of disease A (both cases 
and controls) to investigate the risk of disease B in the current study. We require the 
covariates in the prior study (those extracted from the registers and measured in the 
field) include the covariates of interest for the current study. The information on the 
survival or censoring time regarding disease B is needed for calculating 
log-likelihood contribution of each individual, which will be showed in Equation (5). 
And the time of onset of both diseases is needed to calculate the probability of 
inclusion provided in Equation (6).  
2.3 The inclusion probabilities in a NCC study 
Within the cohort framework, we are using B-sampling method proposed by Cai and 
Zheng [30]. The other popular method is F-sampling, which is to sample the controls 
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without replacement. The B-sampling method assumes each of the nested case-control 
study includes all cases of the disease of interest in the cohort, the probability of being 
selected into one NCC study is 1 for those who develop the disease of interest before 
the end of follow-up. The probability that individual i is ever selected as a control in 
this NCC study is not intuitive to calculate. But the probability of individual i is never 
selected as a control is the union of not being selected at each event time, which can 
be expressed as: 
     (3) 
where the product is taken over all cases of k that occur before tik (the onset of disease 
k or censoring time in study k for individual i); M
k
ij is the number of individuals, not 
including the case j, that share the same matching variables as individual i and are still 
at risk for disease k at time tjk; mk is the number of controls selected per case in study 
k; the indicator function I(Uj = Ui ) denotes whether individual i has the same values 
for the matching variables as case j, i.e. whether individual i has the potential to be 
selected as a control at time tjk. The restriction for tjk is that it has to be within the 
time frame from the start of follow-up si to the event time tik for individual i. If 




2.4 Combining the two NCC studies 
With all the information available as described above, we now want to re-use study A 
information to help increase the efficiency of study B. Salim et al. [27], based on an 
earlier proposal by Samuelsen [25], suggested maximizing the following weighted 
likelihood to estimate θB = (βB, 
γB) using the combined data ΩA U ΩB, where Ωk denotes the set of subjects selected 
into the study of disease k. 
  (4) 
where is the log-likelihood contribution of individual i given by the following: 
          (5) 
with yi being the binary indicator taking the value one if individual i is a case in study 
B. The weight ωi is calculated as the inverse of the probability of inclusion in either 
study (1/pi). The probability of inclusion in the combined study is  
pi = 1 − (1 − piA) * (1 − piB).            (6) 
When there is no association between the two diseases, study A can be viewed as a 
random subset of the study cohort, then the partial likelihood becomes:  
15 
 
     (7) 
for study A data. By maximizing jointly the partial likelihoods for study A using 
Equation (7) and for study B using Equation (2), the estimates of βB and γB will be 
unbiased. But if the two diseases are associated, disease A subjects are likely to be 
either an over-representation or under-representation of disease B cases, and will 
eventually lead to biased estimates. The Horvitz-Thompson approach with the 
appropriate weights provides a solution to this situation and provides unbiased 
estimates. The Horvitz–Thompson approach weights the prospective log-likelihood of 
each individual by the inverse of the probability pi that they are selected into the 
sample. We will demonstrate this statement later in the Simulation session. 
Parameter estimation To obtain parameter estimates, we maximize Equation (4) 
with respect to θB and λ0B(t). In practice, this can be done by using routine parametric 
survival regression models that accommodate sampling weights, such as the survreg 
function in the R survival package. For some users, the need to specify a parametric 
distribution for the baseline hazard functions could be seen as a nuisance. In principle, 
this can be avoided by estimating θB using a routine that employs a partial likelihood 
method such as the coxph function in R with the appropriate weight. For our data 
analysis in the simulation, we use the weighted likelihood (Equation 4) with constant 
baseline hazard function to estimate θB. While for the two data application analyses, 
we use the weighted likelihood with Weibull baseline hazard function. 
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Variance To obtain the variances for the estimates, we need to maximize Equation (4) 
and use the robust sandwich variance formula: I
-1
 + I
-1Δ I-1. Here I is the Fisher 
information matrix of θB = (βB, γB), and can be obtained by taking negative of the 
second derivative of the Equation (4): loglw(θB) with regard to θB. In the robust 
sandwich variance formula we have the Δ term, which is considered as the “penalty” 
we get for pretending all the individual log-likelihood contributions are independent. 
Samuelsen [25] and Salim et al. [27] suggested the formula of Δ for our design with a 
large cohort size N: 
  (8) 
where pi and pi’ is the probability of being included into the combined study for 
individual i and i’, Si(θB) is the unweighted score vector for individual i (the first 








Chapter 3 Simulation Procedure 
3.1 Simulation of Cohort Data 
We simulated an illustrative study cohort, by generating 5,000 values of gender, age, 
binary exposure and times of two events. Without losing generalizability, we 
generated the variable “gender” as a Bernoulli random variable with probability 0.5 
and the variable baseline age “age0” from a normal distribution with mean 40 and 
standard deviation 8. All age values generated were rounded to the nearest integers. 
The binary exposure variable x was generated as a Bernoulli random variable with the 
probability of exposure given by the following logistic regression model, 
     (9) 
Given the age, gender and exposure values, the times of onset for the two diseases 
were generated independently from each other using the following proportional 
hazard functions with constant baseline hazards: 
    (10) 
In this way, the two diseases are generated as conditionally independent given shared 
risk factors: age and gender. The time scale t is time on study so that all subjects enter 
the study cohort at time t = 0. The constant baseline hazards were set to λ0A(t) = 
0.00002 and λ0B(t) = 0.00007 respectively. The baseline hazards were chosen to be 
close to zero, which mimic the small hazard of developing a disease, especially 
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cancers in the real world. The mean of simulated times of onset is about 44.2 for 
disease A and 67.9 for disease B, which would translate to 3-6 years if the unit of 
time is month.  
The parameter of primary interest is βB, the log hazard-ratio (HR) for disease B in the 
underlying cohort. Using the above set-up we generated 500 cohorts, each of size N = 
5,000, for three underlying values of βB, corresponding to hazard-ratios of exp(βB)= 
1.2, 1.5 and 2.0. The three values for exp(β) were chosen to cover the range of typical 
risk estimates encountered in epidemiological research. Across the 500 cohorts, the 
correlation ranges from 0.16 to 0.14 between gender and x and 0.37 to 0.44 between 
age and x. As the correlations are not very high, the collinearity between age, gender 
and x should not affect the analysis. 
The simulations with exp(βB) = 1.2 were repeated with the following hazard 
functions in order to generate less overlap between the distributions of age at baseline 
for cases of the two diseases:  
       (11) 
The constant baseline hazards were set to λ0A(t) = 0.00002 and λ0B(t) = 0.000115 
respectively, and as before, 500 cohorts of size 5,000 were simulated. 
Models (10) and (11) represent situations with more and less overlap in the matching 
variables in the two studies. In the case of more overlap, the mean baseline age for 
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cases of disease A was 46.7 (95% CI: 41.7, 44.8) and for cases of disease B was 43.3 
(95% CI: 41.7, 44.8). With less overlap, the mean baseline age for cases of disease A 
was 51.5 (95% CI: 50.0, 52.6) and for cases of disease B was 41.8 (95% CI: 40.1, 
43.4). 
Copula When the two disease outcomes are associated, simple technique for NCC 
studies will result in biased estimates, but the Horvitz-Thompson approach with the 
appropriate weights will provides unbiased estimates. What we have shown above is 
based on the assumption that the two diseases are correlated by shared risk factors. It 
is possible that the dependence level between the two outcomes will affect the results. 
We perform another set of simulation, where the two onsets are conditionally 
dependent and the dependence is assumed to follow Clayton copula:  
       (12) 
where S(tA) and S(tB) are the marginal survival functions for the two diseases, α is 
the copula parameter, which we assign three values to it: i) α → 0 when the two 
diseases have little dependence and can be viewed as independent; ii) α = 1.3 when 
the two diseases have some large homogeneous dependence (referred as “HomD” in 
the subsequent section); iii) α = exp (0.3 + 1.8 * age + 1.2 * gender) when the levels 
of dependence among the two diseases are heterogeneous across different strata of the 
(age, gender) values (referred as “HetD” in the subsequent section). Clayton copula is 
chosen for the bivariate survival function as it has the equivalence of using gamma 
distributed frailties in the marginal hazard functions. 
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3.2 Nested case-control studies 
For each simulated cohort, we conducted two nested case-control studies and allowed 
the length of the follow-up period in the two studies to vary in order to achieve 100 
cases in each study. For each case, controls were chosen using exact matching on 
gender and 5-year age group with the number of controls varying from 1 to 5 per case 
for the prior study, and 0 to 5 for the current study. For a current study with at least 
one control per case, the data was analyzed using standard conditional logistic 
regression to estimate the parameter of interest (log hazard ratio, βB). Note that in this 
case the weighting approach of Samuelsen [25] could be used to improve precision 
but we chose to use the well-known conditional logistic regression model which is the 
default method for nested case-control data in standard statistical software. 
To estimate βB using the combined data from studies A and B, we used the weighted 
likelihood method described in Chapter 2, where an individual in either data set 
entered the analysis as a single record. For any individual who was selected as a case 
in both studies, we kept the case with the new outcome of interest, and for those 
chosen once as a case and once as a control, we kept the case record. For individuals 
chosen as controls in both studies, the simulated data contains their information in 
duplicate, so that only one of the records is kept in the analysis data set. For all 
individuals, the appropriate weights were computed as the inverse of the probability 
of inclusion given by Equation (6). No modification to the probability of inclusion 
formula was needed for those individuals selected more than once in either study or 
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across both studies, as the formula takes this possibility into account. The variances 
for the unbiased estimates obtained by maximizing Equation (4) were estimated using 
the robust sandwich variance formula in Chapter 2 section 2.4. 
3.3 Relative efficiency 
For each set of 500 cohorts generated under the same underlying hazard ratio, the 
estimates of βB from the conventional analysis (conditional logistic regression) of the 
current study and from the weighted likelihood analysis of the combined data were 
saved and the average and variance of the log hazard ratio estimates across 500 
datasets were calculated. The relative efficiency was calculated as the ratio of the 
empirical variance of the log hazard ratio using the combined data from study A and 
B and the empirical variance of the log hazard ratio using only the current study and 
this relative efficiency was averaged over the 500 simulations. In order to show how 
the efficiency of the analysis of the combined data relative to the analysis of only 
study B changes as a function of the number of prior subjects (in study A) or controls 
(in study B) per case, a contour plot was created with isolines connecting points with 
the same relative efficiency.  
3.4 Effective number of controls 
A natural question for researchers interested in re-using prior subjects as controls is 
how much effective information the prior subjects provide for the new outcome, 
expressed in terms of the equivalent number of newly sampled controls. To answer 
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this question, we introduce the concept of effective number of controls. We first 
construct two curves displaying the variance estimates as a function of the ratio of 
number of controls to number of cases, for studies that (i) use only newly sampled 
controls and (ii) rely exclusively on prior data for controls. Note that the variance 
estimates needed to construct these two curves are readily available as they were 
saved as part of the simulation studies above. The effective number of controls is then 
determined by locating a pair of points on the curves that would yield the same 
variance estimate. In practice, locating this pair of points involves an approximation 
using the approx function in R.  
The added benefit of expressing the number of prior subjects in terms of the number 
of newly sampled controls is that one can perform power calculations for studies that 
use prior subjects using any available software that has the facility to compute power 
for conventional nested case-control studies. 
All simulations and data analyses were conducted using R 2.10.1 [31].  
3.5 Simulation Results 
For all our simulated scenarios, we obtained unbiased estimates from analysis of the 
combined data. As an illustration, Table 3.1 presents the results from the simulation 
using model (10) with β = 0.18 (hazard ratio, HR=1.2). Results for the other scenarios 
with different β values are all similar and shown in the Appendix B.  
Note that the numbers in the top margin of Table 3.1 are the numbers of controls per 
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case for study B, which vary from 0 to 5. The numbers in the left margin are the 
numbers of prior subjects in study A per case of B: the available prior subjects vary 
from 200 (100 cases and 100 controls) to 600 (100 cases and 500 controls), which 
translates to a ratio of prior subjects to new cases of 2 to 6. 
Table 3.1. Average estimates from 500 simulations with β = 0.18 (HR=1.2). Numbers 
in parentheses are the statistical efficiencies of analyses that use only data from study 
B relative to analyses that include prior data from study A 
 
 
Efficiency The numbers in parentheses in Table 3.1 show how the relative efficiency 
varies with the number of controls available from the two studies. Here we define the 
relative efficiency as the ratio of the estimated variance using the combined data to 
the estimated variance using only study B. For example, the underlined value of 0.82 
indicates that the variance will be reduced by 1 - 0.82 = 18%, when a study with two 
controls per case is supplemented by four prior subjects per case. In the special case 
where there are no newly sampled controls in study B (the 1st column of estimates in 
Table 3.1), the relative efficiency cannot be computed, as it is not possible to estimate 
the parameters using cases only. 
For a fixed number of subjects in study A, the rows of Table 3.1 provide information 
on how the relative efficiency (in parentheses) changes with different numbers of 
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controls in study B. With increasing numbers of controls in study B, the relative 
reduction in the estimated variance decreases; for example the first row illustrates that 
the potential gain from re-using two prior subjects per new case varies from about one 
fourth (1 - 0.77 = 23%) for a current study with one control per case to almost no 
reduction (1 - 0.97 = 3%) for a current study with five controls per case. For a fixed 
number of controls per case in the current study, the pattern in each column of Table 
3.1 (in parentheses) shows that as the number of prior subjects increases there is a 
predictable gain in efficiency. Note that supplementing control information using prior 
subjects results in a return of at most 14% gain in efficiency if the current NCC study 
has at least three controls per case. However, for a current study with only one or two 




Figure 3.1. Contour plot of relative efficiency (β = 0.18). 
The relationship between the numbers of controls in both studies and the relative 
efficiency can be better illustrated using a contour plot (see Figure 3.1). For example, 
in a current study with three controls per case, we interpolate the relative efficiency of 
re-using four prior subjects per new case, by checking where the (4, 3) coordinate 
falls. The relative efficiency for this scenario will be between 0.85 and 0.90, which 
means a reduction in the estimated variance of 10 to 15% when the combined data are 
used. 
Efficiency relative to using only available prior data The changes in variance with 
26 
 
the number of controls available from the two studies are presented in Table 3.2(a) 
where relative efficiencies for estimating β = 0.18 (HR = 1.2) in model (10) are 
computed using as reference a study that uses only the available prior data (i.e. 
samples no new controls). If no controls are sampled in study B, increasing the 
number of prior subjects in study A from two to four per case results in a substantial 
reduction (approximately 40%, from 0.130 to 0.078) in the variance, with only small 
further reductions when the number of prior subjects in study A is further increased 
up to six per case. The values in columns 3 to 7 of the table are the estimated 
variances of the log hazard ratio using the combined data from study A and B and the 
numbers in parentheses show the variance as a percentage relative to a study that only 
uses the available prior data. Inspecting the pattern of the variance values, we see that 
acquiring newly sampled controls always results in better efficiency, but the largest 
increment in relative efficiency, regardless of the number of prior subjects, is always 
observed when the number of newly sampled controls is increased from 0 to 3 per 
case. However, the number of prior subjects matters when considering the maximum 
possible gain in relative efficiency. When there are two prior subjects per case, the 
relative efficiency gain can be up to 53.6% = 100% − 46.4% (with 5 newly sampled 
controls per case) but when there are six prior subjects per case, the relative efficiency 
gain is at most 14.5%. 
The gains in efficiency in Table 3.2(a) could be considered as optimistic estimates as 
the age distributions of the two studies are similar. In Table 3.2(b) we present the 
results from the setting where the two studies have different age distributions. As 
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might be expected, the estimated variances of the log hazard ratio are much larger 
than before, especially when no new controls are selected in study B. The relative 
gain from increasing the number of prior subjects from two to four per case is even 
more substantial, with a reduction of 66.7% (from 0.441 to 0.147). However, unlike in 
Table 3.2(a), a substantial reduction is still observed when the number of prior 
subjects is increased further up to six per case. Similar to Table 3.2(a), the largest 
increments in relative efficiency, regardless of the number of prior subjects, are 
observed when the number of newly sampled controls increased from 0 to 3 per case. 
Perhaps, the most striking difference with Table 3.2(a) lies in the maximum relative 
efficiency gain when acquiring newly sampled controls. With two prior subjects per 
case, the maximum relative efficiency gain can be up to 1 - 13.3% = 86.7% when five 
new controls per case are acquired. The corresponding gain in Table 3.2(a) was only 
53.6%. Similarly, with six prior subjects per case, the maximum relative efficiency 
gain can be up to 1 - 53.0% = 47.0%, compared to the corresponding value of 14.5% 
in Table 3.2(a). These observations highlight the importance of newly sampled 




Table 3.2 (a) and (b). Variance of β using the combined data set for different 
numbers of prior subjects (study A) and numbers of controls (study B), relative to the 
number of cases in study B (β = 0.18). Numbers in parentheses show the variance as a 
percentage relative to the variance obtained using only available prior data. 
Effective number of controls Figures 3.2(a) and (b) show the relationship between 
the number of controls (prior or newly sampled) per case and the estimated variances 
for a hazard ratio of 1.2 (i.e. β = 0.18) when the age distributions of the two studies 
have (a) more overlap and (b) less overlap. The dashed lines represent studies that 
combine prior data with new cases, while the solid lines represent studies that sample 
new controls and do not use prior data. The horizontal axes in Figure 3.2(a) and (b) 
indicate the number of newly sampled controls per case for the solid line and the 
number of prior subjects per new case for the dashed line. To estimate the number of 
prior subjects that are needed to achieve the same estimated variance as 2 newly 
sampled controls per case, we draw a horizontal line from the point on the solid curve 
where the abscissa is 2 and find where it intersects the dashed curve. Thus from 
Figure 3.2(a) the required number of prior subjects per case is about 4, so that a study 
that uses 4 prior subjects per case is as effective as a study that samples 2 new 
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controls per case. 
 
Figure 3.2. (a) and (b) Variance estimates for β = 0.18 as a function of number of 
controls per case, with dashed lines representing studies with new cases and prior data, 
and solid lines representing studies with newly sampled controls for studies with (a) 
much more overlap in age distributions and (b) less overlap (≈ 50%) in age 
distributions. (c) and (d) Effective number of controls as a function of the ratio of 
prior subjects to the number of new cases derived from (a) and (b) respectively. 
In other words, for a new study with 100 cases, re-using 400 subjects from a prior 
study is as effective as sampling 200 new controls. We obtain a similar result for the 
same age distributions but with larger hazard ratios, i.e. HR = 1.5 and 2.0 (results not 
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shown). Where there is weak overlap in the age distributions of the two studies, 
(Figure 3.2(b)), we obtain a much different result: more than 6 prior subjects per case 
are needed to be as effective as 2 newly-sampled controls per case. 
Figure 3.2(c) and (d) illustrate the relationship between the number of prior subjects 
and the effective number of controls, for β = 0.18 and the two different levels of 
overlap in the age distributions. As expected, the actual curves obtained are below the 
identity line, as the prior subjects are less effective than newly sampled controls. 
From Figure 3.2(c), we see that 3, 4, 5 and 6 prior subjects per new case are as 
effective as 1.5, 2.0, 2.8 and 3.5 newly sampled controls respectively, which means 
that for a study with 100 cases, 300, 400, 500 and 600 prior subjects are as effective 
as sampling 150, 200, 280 and 350 new controls. Figure 3.2(d) shows that for a prior 
study with much different age distribution, 500 and 600 prior subjects are only as 
effective as sampling 62 and 90 new controls for 100 new cases. 
Copula We obtained similar results for the relative efficiency and variance estimates 
under the other scenarios (with different dependence levels between the two disease 
outcomes). Here we show two tables which are similar to Table 3.1 and 3.2, and we 
can see that the results are quite consistent with Table 3.1 and 3.2. We conclude that 





Table 3.3. Average estimates of the statistical efficiencies of analyses that use only 
data from study B relative to analyses that include prior data from study A with β = 
0.18 (HR=1.2) when there are homogeneous large dependence and heterogeneous 
dependence between the two outcomes. 
HomD Study B 
Study A 1 2 3 4 5 
2 0.80  0.94  0.98  1.00  1.00  
3 0.72  0.86  0.91  0.93  0.95  
4 0.68  0.82  0.87  0.90  0.92  
5 0.66  0.80  0.85  0.88  0.90  
6 0.65  0.79  0.84  0.87  0.89  
 HetD Study B 
Study A 1 2 3 4 5 
2 0.81  0.94  0.98  1.00  1.00  
3 0.73  0.86  0.91  0.94  0.95  
4 0.69  0.82  0.87  0.90  0.92  
5 0.67  0.80  0.85  0.89  0.90  
6 0.65  0.79  0.84  0.87  0.89  
Table 3.4. Variance of β using the combined data set for different numbers of prior 
subjects (study A) and numbers of controls (study B), relative to the number of cases 
in study B (β = 0.18) when there are homogeneous large dependence and 
heterogeneous dependence between the two outcomes.  
 
HomD Study B 
Study A 0  1 2 3 4 5 
2  0.147  0.092  0.079  0.074  0.071  0.069  
3  0.098  0.082  0.073  0.068  0.066  0.065  
4  0.083  0.078  0.070  0.066  0.064  0.063  
5  0.075  0.076  0.068  0.064  0.063  0.061  
6  0.070  0.074  0.067  0.064  0.062  0.061  
 
HetD Study B 
Study A 0  1 2 3 4 5 
2  0.147  0.093  0.079  0.074  0.071  0.069  
3  0.098  0.083  0.072  0.068  0.066  0.064  
4  0.082  0.079  0.069  0.066  0.064  0.062  
5  0.074  0.076  0.068  0.064  0.062  0.061  
6  0.070  0.074  0.066  0.063  0.061  0.060  
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Chapter 4: Illustrative datasets 
4.1 Anorexia data 
There are two published Swedish case-control studies nested in the overlapping 
cohorts of girls born from 1973 to 1984 and 1973 to 1979. One investigated the 
association between birth characteristics and the risk of anorexia nervosa [32]: cases 
were 778 girls born between 1973 and 1984 who had been hospitalized with a 
diagnosis of anorexia nervosa (International Classification of Diseases and Related 
Health Problems (ICD) version 9 code 307B). For each case, 5 controls were selected, 
individually matched by year and hospital of birth, from girls alive and without a 
diagnosis of anorexia nervosa at the time of diagnosis of the case. After removing 
subjects with missing values and duplicated subjects, the total size of the anorexia 
data is 4619.  
The second study investigated prenatal and perinatal risk factors for schizophrenia in 
children born in Sweden between 1973 and 1979 [33]. In this study, 58 girls aged 15 - 
21 years were diagnosed and each case had 5 controls, individually matched on year 
of birth and hospital of birth. After removing 1 duplicated subject, the number of girls 
in the schizophrenia dataset is 347. 
To illustrate the use of the prior data from schizophrenia study to supplement the 
current study of anorexia, we compared the estimated parameters and their variances 
from various analyses that excluded some/all of the controls from the anorexia study. 
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We present the estimates of the effects of two binary risk factors: gestational age less 
than 33 weeks and birth trauma defined by the ICD version 8 code 772. The choice of 
risk factors to be investigated here is restricted; as we mentioned in the Chapter 2, 
only covariates available in both the prior and the current NCC studies can be studied 
using our method. In the analysis of the combined data, proportional hazards models 
[25] are used under assumption of Weibull baseline hazard functions. For power 
calculation, we used the ESPRESSO software package [34]. 
4.2 Results 
Combining the anorexia and schizophrenia data sets described above, there were 3 
individuals who were cases in both studies and we kept the record with the new 
disease of interest (anorexia nervosa). Table 4.1 presents estimates of the effects of 
the binary risk factors obtained using the original anorexia data set (5 controls per 
case), the anorexia data set with 1 or 2 randomly selected controls per case, and the 
anorexia data with no controls or only 1 randomly-selected control per case combined 
with the schizophrenia data. The analyses of the subsets of the original anorexia data 
(i.e. where fewer than 5 controls per case are used) yield larger standard errors and 
slightly different estimates (2nd and 4th rows of Table 4.1) due to the smaller sample 
sizes and the randomness introduced by selecting a subset of the controls. For the 
analysis of the combined data with 0 or 1 control per anorexia case, our estimates are 
similar to those obtained from the full data, but with larger standard errors as expected. 




Table 4.1. Log hazard ratio estimates with anorexia as outcome: numbers in square 
brackets are the numbers of controls per case selected from the anorexia data, and Scz 
indicates re-use of the schizophrenia data 
 
As the results across simulations with different levels of HR values are all similar 
(Table 3.1 and Appendix B), the respective efficiency curves are ought to be similar 
too. Figure 3.2 can be applied even the effect estimates for exposures of interest are 
not exactly the same as in simulation studies. Figure 3.2(c) is used to estimate the 
effective number of controls for the last row of Table 4.1, where only prior 
schizophrenia subjects are used as controls for the anorexia cases. Assuming the 
anorexia prevalence in the population is 0.3% [35], a power calculation indicates that 
to achieve 80% power at 5% significance level for a binary exposure with hazard ratio 
2.0 and exposure prevalence of about 3% (which is very similar to birth trauma in our 
data), we need to have 778 cases and 778 newly-sampled controls (1 control per case). 
Using Figure 3.2(c), we estimate that to achieve the same level of effectiveness as 1 
newly-sampled control per case, we would need about 2.6 prior subjects per anorexia 




4.3 Contra-lateral breast cancer data 
Our second data illustration involves data from two studies nested in a cohort of 
women diagnosed with breast cancer in Stockholm between 1970 and 1999 and 
followed up until the end of 2005. First of all, we know that nearly all breast cancer 
patients in Sweden are treated within the national health care system and the treatment 
regimens are similar in different parts of the country. This will ensure we do not need 
to deal with confounding by treatment. The Swedish Cancer Registry (SCR) was 
started in 1958 and receives reports on newly diagnosed cancers from both 
pathologist/cytologists and physicians. Reporting to the register is compulsory, and 
most diagnosed patients are thus reported from at least two independent sources and 
96% of all cancers in Sweden are reported to the register [36]. In addition, a personal 
identification number is used for all population registers in Sweden and consists of six 
digits for year, month and day of birth, supplemented with four digits representing the 
place of birth, sex and a check digit. This identification number allows us to track the 
person across different registers, such as cancer register and death register, also track 
across different sources of the reporting of cancer. 
One study (considered as the prior study) identified ninety-four women who were 
diagnosed with lung cancer at least one year after their first breast cancer diagnosis. 
Since information on risk factors was to be obtained from medical records, a nested 
case-control design was used to reduce the workload of manual abstraction. We 
identified one hundred and twenty-eight controls who were free from lung cancer at 
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the times of diagnosis of the cases. In addition to time since the first breast cancer 
diagnosis as everyone survive for at least one year since their first breast cancer 
diagnosis, the controls were matched on age and calendar period (in decades) of 
diagnosis.  
The second study (considered as the current study) has identified five hundred and 
fifty-six women who developed metachronous bilateral breast cancer (which is a 
second primary cancer in the contralateral breast at least one year after the first breast 
cancer diagnosis in our definition), but to date no controls have been selected. 
Bilateral breast cancers are classified in the literature as being synchronous (occurring 
at the same time) or metachronous (occurring at some time after the diagnosis of the 
first primary breast cancer). This definition has been interpreted in a number of 
different ways. Bilateral breast cancers have been defined as synchronous in some 
studies if they occur within 6 months of the first breast cancer and, in other studies, if 
they occur within 1 year of the first breast cancer [37]. We use the latter criteria, 




Figure 4.1. The contra-lateral breast cancer data structure. 
The structure of the two studies can be seen as Figure 4.1, besides what have been 
mentioned, the original data have some data errors which are cleared out during the 
data cleaning process. Here in Figure 4.1, “data error” in Study A have two possible 
conditions: subjects had lung cancer diagnosis before the breast cancer diagnosis and 
subjects had a wrong record of death before developing the lung cancer. Some other 
subjects are also excluded from the analysis, such as those with “Latency <1yr” are 
considered as synchronous breast cancer as we have mentioned; those with “1st BrCa 
out of time range” are those who had their first breast cancer diagnosis before year 
1970 or after year 1999 and those subjects in Study A with “area out of Stockholm” 
are who got their first breast cancer diagnosis in the rest of Sweden. The final analysis 
only includes 94 prior cases, 128 prior controls together with 556 CBC cases as 
marked in bold type in Figure 4.1. 
Whole Study 








Data Error: 13 
Latency < 1yr: 3 
1st BrCa out of 
time range: 700 
Area out of 
Stockholm:  601 
Study B CBC 
1317 
Suitable 556 
All CBC case 
Latency <1 yr: 
508 
1st BrCa out 




We applied our method to analyse the combined data from these two studies, in order 
to estimate the effects of age at first breast cancer diagnosis and family history of 
breast cancer on the risk of developing a CBC. Many other factors, such as treatments, 
tumor size and histology types of the first breast cancer are potential risk factors for 
CBC and researchers might be interested to study, but due to data availability, we do 
not have all the data needed to study these risk factors.  
4.4 Results 
Combining the lung cancer and contra-lateral breast cancer (CBC) data sets described 
above, Table 4.2 presents estimates of the effects of age at diagnosis of the first breast 
cancer and family history (adjusted for period of diagnosis of the first primary breast 
cancer) on the risk of CBC. The estimates are similar to those in other published work 
[38, 39, 40]: there is a statistically significant higher rate of CBC in patients with a 
positive family history (HR=1.50, 95% CI: 1.03-2.16), while the risk of CBC 
decreases with increasing age at first primary breast cancer (HR=0.66, 95% CI: 0.50, 
0.86 for each year increase in age). 
Figure 3.2(c) is used instead of 3.2(d) to estimate the effective number of controls for 
the data analysis, since the distributions of age at onset of the two diseases are similar 
(lung cancer: mean age 68.78, upper and lower quartiles = 61, 74; CBC: mean age 
64.42, upper and lower quartiles = 55, 74)). Assuming the CBC prevalence in the 
population is 3%, a power calculation indicates a study of 746 cases and one newly 
sampled control per case can achieve 80% power at 5% significance level for a binary 
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exposure (family history) with HR=1.5 and exposure prevalence of about 30% 
(representative of our data). Using Figure 3.2(c), we estimate that to achieve the same 
level of effectiveness, we would need approximately 1940 prior subjects for a study 
with 746 cases. 
Table 4.2. Estimates of the effect of age and family history on the risk of contralateral 
breast cancer (CBC) obtained from analysis of incident cases of CBC combined with 
a previous nested case-control study of lung cancer in the same cohort. Estimates are 














Chapter 5: Discussion 
We have investigated in detail the impact of the number of controls per case in the 
prior and current studies on the relative efficiency when re-using prior subjects in a 
nested case-control study. Silvey [41] suggested that a nested case-control study 
needed at least four controls per case in order to achieve the same efficiency as a 
cohort study. Figure 3.2(c) shows that if using prior subjects with similar age 
distribution, this would translate into about five prior subjects per case. In practical 
terms even four prior subjects per case may achieve good efficiency, as evidenced by 
our observations from Table 3.2(a). In contrast to this optimal situation, Figure 3.2(d) 
shows that if using prior subjects with a much different age distribution, this would 
translate to a much larger number of prior subjects (more than 6 per case), which 
might not be practical.  
The ability to re-use nested case-control data offers researchers several cost-saving 
strategies when designing a new study. Using standard statistical software, we 
conducted power calculations based on the concept of the number of “effective 
controls” the existing data would contribute to the new study. This ability to estimate 
power is very important because it determines whether researchers interested in 
re-using prior nested case-control subjects can rely exclusively on the available prior 
data for control information or additional newly sampled controls are needed. If 
sufficient data are available from the prior study for control information, the 
investigators may proceed to gather only new cases, and conduct a valid analysis of 
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the combined data using our method. Where prior data are available but the sample 
size is deemed inadequate, the investigators will need to supplement with new 
controls to achieve the required study power. Where only a small number of new 
controls need to be gathered, the cost savings from using the existing data can be 
considerable. However, where the existing data is only a small fraction of what is 
required for the new study, the small cost savings needs to be balanced against the 
additional efforts required for non-standard data analysis. 
We want to emphasize that we used a limited range of parameters for our simulation; 
researchers need to be cautious when they want to generalize the results (tables and 
figures). For example, Figure 3.2 only gives a general guide for the effective number 
of controls as it is valid for a moderate HR of 1.2 (log HR is 0.18). When researchers 
are dealing with different overlapping in the matching variables, the exact effective 
number of controls needs to be calculated for each unique situation. One situation 
where the curve of effective number of controls can be constructed is when the 
researchers have a prior NCC study with four or five controls per case, researchers 
can plot out the effective number of controls curve by re-using the prior NCC study 
while pretending there are 1, 2, 3, 4, and 5 controls per case. They can obtain five 
different estimated variances for the log HR value, and subsequently construct the 
curve by connecting the 5 point estimates. If the prior NCC study only has three or 
less controls per case, similar steps can be used to construct the curve but the curve 
will be less reliable in a way since extrapolation for larger number of control is 
needed. In addition, it should be noted that the coefficients of our hazard functions 
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(Equations 9 and 10) are arbitrarily chosen. However, our main interest is being able 
to estimate the hazard ratios and SE unbiasedly, we do not think this choice will be 
overly critical.  
Our method applies to data that have been sampled from a well-defined cohort, as 
only then can one compute the appropriate weights. While there are a number of such 
well-known cohorts with extensive covariate data gathered through field work (e.g. 
Nurses Health Study, Women’s Health Initiative, Framingham Study), any 
case-control study conducted within a population with comprehensive registration of 
its members and their health events also has the potential for re-use of the data. In 
particular, NCC studies that sample subjects from population-based registers offer the 
potential for re-use, since the “study base” is well characterized by the registers. 
However, these NCC studies typically involve the collection of covariate information 
in addition to what is available from the registers: indeed there is little motivation to 
do a case-control study if only registered covariates are modeled, since there is little 
or no additional cost in obtaining data for the entire population and conducting a 
cohort analysis.  
Our method is only useful for studies where the covariates in one study (those 
extracted from the registers and measured in the field) include the covariates of 
interest for the second study. This is unlikely to occur where a different disease entity 
is to be investigated in the second study, but likely to occur where exposures are 
obtained from data records for studies of related diseases such as cancers at different 
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sites, different cardiovascular diseases (e.g. stroke and MI) or related psychiatric 
disorders. In our illustrative example of CBC, the underlying cohort consists of 
women with a diagnosis of breast cancer, who are followed up from diagnosis for the 
occurrence of a CBC. A prior study of lung cancer following breast cancer was 
conducted within this same cohort, and considerable time and effort was invested in 
extracting covariate data from medical records. These covariates include potential risk 
factors that are of interest in the new study, and so the re-use of the existing data may 
provide significant cost-savings. 
The gains in efficiency and power from re-using existing data in our simulation 
studies should be regarded as optimistic estimates, since these studies were conducted 
in the same cohort and used the same matching variables. While this situation may 
occur for two studies conducted by the same researchers within the same cohort, there 
will be many applications where these conditions are not met. In practice the two 
studies may be conducted in overlapping cohorts so that not all records from the prior 
study are available for inclusion in the new study, and different matching variables 
may have been used (see the next paragraph). It is also common in practice that the 
two diseases are closely related, such as colon cancer and breast cancer. In this 
situation, we suggest modifying the hazard function of a case; such that its hazard of 
getting the second disease changes once we know it is a prior case. When the two 
diseases are highly associated, we would expect less number of unique subjects that 
can be re-used from the prior study. This will certainly affect the study power or 
relative efficiency. Sometimes, for some logistical and biological reasons, researchers 
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may not want to re-use the cases of the prior study [42, 43] but only the controls,  
this way will reduce the study size and affect the study power even more.  
Our method is applicable to the setting where matching variables are different, but 
there will be a loss in efficiency. Using different age distributions for the two diseases, 
we demonstrated the lower information (and hence smaller number of effective 
controls) in prior data with a different distribution for the matching variable. Power 
will be further reduced where there are several matching variables that differ in their 
distributions. Thus finely matched NCC data for a specific study are less likely to 
contribute substantial power to the study of a new outcome, but many studies that 
match only on age categories and sex offer good potential for re-use. 
The ability to re-use existing NCC data has the potential for significantly reduced 
costs in genetic and molecular epidemiology studies, where exposure measurements 
can be expensive [44, 45, 46]. However, in such studies, it would rarely be advisable 
to rely entirely on existing data for controls, since the speed of technological change 
could result in serious confounding due to changes in platforms or procedures since 
these control measurements were made. However, if the study gathers some new 
controls, and if these can be measured on both old and new technologies, these 
validation data will enable adjustment of the prior measurements. Studies that have 
access to stored biological samples from previous studies (as opposed to stored data) 
do not have to contend with this problem, but may have serious bias if the individual 
matching is broken and there are differential batch effects and/or sample deterioration 
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over time between cases and controls. Measurement of genetic polymorphism will 
generally not have this problem due to the stability of DNA.  
Finally, it is worth noting that obtaining the correct probability of inclusion is 
important for the validity of our likelihood method. Here, we compute the probability 
using formulae that reflect the incidence density sampling used in NCC studies. 
Although these formulae are easy to compute and intuitive, they may be unstable for 
studies employing fine matching. In such situations, other ways for computing the 
probability of inclusion are available (see Kim and De Gruttola [47]; Samuelsen et al. 
[48]) and should be considered as alternatives to our approach here.  
In conclusion, although it may not be the most efficient statistically [19], the weighted 
likelihood method used here is intuitive and practical in settings where data on 
covariates and outcomes of interest are available, and the matching in the two studies 
is sufficiently similar for the effective number of controls to be reasonable. Our focus 
is on the re-use of existing nested case-control data, but where new studies are being 
planned that intend to make use of expensive molecular or genetic data for multiple 
outcomes, a case-cohort approach [49] is likely to be preferable. Areas for further 
research include the investigation of more flexible designs that do not require a fixed 
number of controls per case (e.g. Karvanen et al. [50]), use of semiparametric models 
to yield more efficient estimates and the inclusion of a time-dependent covariate to 
accommodate the modification of risk of one disease by presence of the other when a 
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Appendix A (R code for simulation) 
######################################################### 








or = NULL 
beta = log(c(1.2,1.5,2))  #0.18,0.41,0.69 
## The whole simulation repeats for m times in the process 
of searching the extreme value. 
## Running it so many times is just to avoid "being trapped 




for(m in 1:500) { 
for (o in 1:1) { # varying OR = 1.3, 1.6, 3 
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for(q in 1:length(beta)) { #varying Beta 
############################## 
##   generate cohort data   ## 
############################## 
n = 2000 
## matching var [gender (0 or 1) and age (normal dist with 
40,5)] 
gender = sample(0:1,size=n,replace=T) 
age = round(rnorm(n,mean=40,sd=5)) 
###################################### 
##         diff sd: 0, 0.5, 1         ## 
###################################### 
mu = -0.5*((o-1)/2)^2 
rnd.eff = rnorm(n,mean=mu,sd=(o-1)/2) 
## prob of exposure depends on age and gender to create 
dependence ## between disease status and matching var 
conditional on exposure, ## in the final cc sample 
## log odds=log(p/(1+p)) 
logit.prob = 0.5*gender+0.1*scale(age,scale=F) 
## p=exp(log odds)/(1+exp(log odds)) 
exp.prob= exp(logit.prob)/(1+exp(logit.prob)) 
## binary exposure: x (0,1) 
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x = rbinom(n,size=1,prob=exp.prob) 
## generate time of event (1st outcome of interest)  
## prob exposure increasing with time 
u = NULL 
for(i in 1:100) { 
  a = (i-1)/100; b=i/100+1e-08 
  u =c(u, runif(n/100,a,b)) 
} 
#reorder 
u = u[sample(n)] 
## the vil here, not in the formula, is for future use 
cdf = function(p,ui,age,vil,x,indv.eff) { 






for(i in 1:n) { 





      interval=c(0,10000))$root 
} 
######################################################### 
## generate secondary outcome of interest:  
## parameters such that 20% develop disease before 2 yrs 
u2 = NULL 
for(i in 1:100) { 
  a = (i-1)/100; b=i/100+1e-08 
  u2 =c(u2, runif(n/100,a,b)) 
} 
#reorder 
u2 = u2[sample(n)] 
## the difference between cdf1 and cdf2 is only the 
coefficients 
cdf2 = function(p,ui,age,vil,x,indv.eff,beta) { 









for(i in 1:n) { 
    t2[i]= 
uniroot(f=cdf2,ui=u2[i],age=age[i],vil=gender[i],indv.eff
=rnd.eff[i],beta=beta[q],x=x[i],interval=c(0,10000))$root 
    #if(t2[i]>1e-03) print(i) 
} 
############################################### 
## vil=gender (0,1); x=exposure (0,1); age (normal dist); t 
and ## t2 are time of 1st 2nd events 
data = data.frame(t,t2,gender,age,x,coh.id=1:length(x)) 




rep.case[m,o,q]=sum(t2 <= time.stop2 & t <= time.stop) 
timestop[m,o,q,]=c(time.stop,time.stop2) 
############################################### 
## calculating weight: calculate weight for everybody in 
cohort 
## given the number of ctrls in 1st and 2nd studies 
## weight.tab[,,1] contains weight for 1st study with 1 ctrl 
## weight.tab[,,2] for 1st study with 2ctrls and so on 
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## weight.tab2 is the counterpart for 2nd study 
## For each i: weight.tab[,,i] is a matrix with weight[j,k,i] 
refers to weight for subject with age==unique(age)[j], 
## gender==unique(gender)[k] when i controls are needed. 
weight.tab = weight2.tab <- 
array(0,dim=c(length(unique(age)), 
length(unique(gender)),5)) 
for(i in 1:dim(weight.tab)[1]) { 
   for(j in 1:2) { 
     total = sum(age==unique(age)[i] & 
gender==unique(gender)[j]) 
     total.ev = sum(age==unique(age)[i] & 
gender==unique(gender)[j] & t<=time.stop) 
     total.ev2 = sum(age==unique(age)[i] & 
gender==unique(gender)[j] & t2<=time.stop2); 
#print(total.ev2); print("total.ev2"); 
  if(total.ev>0){ 
    if (total>total.ev) {   
 weight.tab[i,j,1:min(total-total.ev,dim(weight.tab)[3]






     if((total-total.ev)<dim(weight.tab)[3])  
   weight.tab[i,j,(total-total.ev+1):dim(weight.tab)[3]] 
= 1 
    }    
  } 
  if(total.ev2>0){ 
    if (total>total.ev2) {     
 weight2.tab[i,j,1:min(total-total.ev2,dim(weight.tab)[




        if((total-total.ev2)<dim(weight.tab)[3])    
weight2.tab[i,j,(total-total.ev2+1):dim(weight.tab)[3]] = 
1 
    }  
    } 
  } 
} 
############### choosing control for each case;  
###### 1/2/3/4/5 controls for each case matched on gender & 
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age cat  
##### Note: we only collect the selected controls+cases' ids  
##### Also each row of slct.id contains ids for the ith cases 
and his/her selected controls (max 'nc1' ctrls). To use these 
ids: eg, if only 1 ctrl is needed then use only the 1st column  
(cases) and the 2nd column (1st ctrl), the subsequent columns 
are for subsequent controls   
id = 1:n 
case1 = id[t<=time.stop] 
nc1 = 5 
ncase = length(case1) 
strata1 = array(0,dim=c(ncase,nc1+1)) 
slct.id = array(0,dim=c(ncase,nc1+1)) 
#cc.data = cbind(y=1,y2=1,data[1,],id=1,weight=1) 
for(i in 1:ncase) { 
   candi = id[data$t>data$t[case1[i]] & 
data$vil==data$vil[case1[i]] & 
abs(data$age-data$age[case1[i]])==0] 
   if(length(candi)>1) { 
     slct.id[i,1:(min(length(candi),nc1)+1)] = 
c(case1[i],sample(candi,size=min(length(candi),nc1))) 




   if(length(candi)==1) { 
     slct.id[i,1:2] = c(case1[i],candi) 
     strata1[i,1:2] = rep(i,2) 
   } 
   } 
   if(length(candi)==0) { 
     slct.id[i,1] = case1[i] 
     strata1[i,1] = i 
   } 
} 
################################################## 
## now do the same thing but for 2nd outcome ##### 
################################################## 
id2 = 1:n 
case2 = id2[t2<=time.stop2] 
ncase = length(case2) 
nc2 = 5 
strata2 = array(0,dim=c(ncase,nc2+1)) 
slct.id2 = array(0,dim=c(ncase,nc2+1)) 
for(i in 1:ncase) { 





   if(length(candi)>1) { 
     slct.id2[i,1:(min(length(candi),nc2)+1)] = 
c(case2[i],sample(candi,size=min(length(candi),nc2))) 
     strata2[i,1:(min(length(candi),nc2)+1)] = 
rep(i,min(length(candi),nc2)+1) 
   } 
   if(length(candi)==1) { 
     slct.id2[i,1:2] = c(case2[i],candi) 
     strata2[i,1:2] = rep(i,2) 
   } 
   if(length(candi)==0) { 
     slct.id2[i,1] = case2[i] 
     strata2[i,1] = i 
   } 
} 
################################################### 
## for each combination of num of ctrls in first and second 
study 
for(j in 1:nc1) { 




## analyse 2nd only using clogit ## 
################################### 
if (k > 0) { 
st2 <- c(t(strata2[,1:(k+1)])) 
st2 <- st2[st2>0] 
study2.id <- c(t(slct.id2[,1:(k+1)])) 
study2.id <- study2.id[study2.id>0] 
cases2 <- !duplicated(st2)  
out <- clogit(cases2~x[study2.id]+strata(st2),data=data) 
par[m,3,j,k,o,q] = out$coef 
var.par[m,3,j,k,o,q] = out$var 
} 
#################################### 
## analyse combined two datasets ## 
#################################### 
y2 <- as.numeric(data$t2<= time.stop2) 
y <- as.numeric(data$t<=time.stop) 
study12.id <-  c(c(t(slct.id[,1:(j+1)])), 
c(t(slct.id2[,1:(k+1)]))) 
study12.id <- study12.id[study12.id>0] 
study12.id <- unique(study12.id) 
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if (k == 0) { 
wt1 <- weight.tab[cbind(match(age[study12.id],unique(age)), 
match(gender[study12.id],unique(gender)),j)] 
wt2 <- rep(0,length(study12.id)) 
} 
if (k > 0) { 






wt <- wt1 + wt2 - wt1*wt2 
wt <- ifelse(y[study12.id]==1 | y2[study12.id]==1,1,wt) 
























## get starting value 
p=c(coxph(Surv(t2,y2)~age+gender+x,data=data)$coef,0.01,0
.0001) 







## re-start search to avoid being trapped at local minimum  
for(i in 1:3) { 




   #print(out$v) 
} 
par[m,1,j,k+1,o,q]=out$p[3] 
## approximate gradient (score) 
f1 = so.loglik.uwt(p=out$p,data=cc.data) 
score = matrix(0,length(f1),length(p))  
for(i in 1:length(p)) { 
  p.prime = out$p; p.prime[i]=p.prime[i]+(1e-04*out$p[i]) 
  f2 = so.loglik.uwt(p=p.prime,data=cc.data) 
  score[,i] = (f2-f1)/(1e-04*out$p[i]) 
} 
pen.term = matrix(0,length(p),length(p)) 
for(i in 1:length(f1)) { 








  var.hat = (solve(out$hess) + 
solve(out$hess)%*%pen.term%*%solve(out$hess)) 
  var.par[m,1,j,k+1,o,q]=var.hat[3,3] 
} 
if(abs(rcond(out$hess))<1e-09) 
  var.par[m,1,j,k+1,o,q]=NA 
######################################################### 






} # end of k 
} # end of j 
#################################### 









} # end of q 
} # end of o 
} # end of m 
proc.time()-start 
repcase=array(0,dim=c(4,3)) 
for (i in 1:4) { 







for (i in 1:1) { 









for (i in 1:1) { 






for (i in 1:1) { 





#2nd only variance 
xyzvar2=array(0,dim=c(6,1,length(beta))) 
for (i in 1:1) { 








for (i in 1:1) { 











contour(x = seq(1, 5, length.out = nrow(z)), 
        y = seq(1, 5, length.out = ncol(z)), 
        z,nlevels = 12,xlab="Number of controls in study A", 
        ylab="Number of controls in study B", 
        labcex = 1.0) 










# plot estimated variance 
plot(x=c(1,2,3,4,5,6),y=c(NA,oldv_1),type="o",ylim=c(ylim
1,ylim2),lty=2,lwd=2, 
   ylab="Estimated Variance",xlab="Ratio of controls to 
cases", 

















   ylab="Estimated Variance",xlab="Ratio of controls to 
cases", 






















prior subjects to new cases", ylab="Effective number of 











prior subjects to new cases", ylab="Effective number of 
controls per new case",main="(d)")  
abline(0,1,col="red") 
############################################# 




so.loglik = function(p,data) { 
  logl = (data$y2)*log(hzrd(p=p,data=data)) - 
cum.hzrd(p=p,data=data) 
  logl = sum(logl/data$weight) 
  logl = ifelse(is.na(logl),-1e+20,logl) 
return(-logl) 
}     
cum.hzrd = function(p,data) { 









so.loglik.uwt = function(p,data) { 
  logl = (data$y2)*log(hzrd(p=p,data=data)) - 
cum.hzrd(p=p,data=data) 
return(logl) 
}     
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Appendix B (Other results) 
Table 3.1 for other simulation settings: 
Average estimates from 500 simulations with beta = 0.41(HR=1.5) 
Study A/B 0 1 2 3 4 5 
2 0.412 0.405 0.408 0.410 0.411 0.411 
3 0.409 0.406 0.406 0.408 0.409 0.409 
4 0.407 0.406 0.406 0.408 0.410 0.409 
5 0.408 0.407 0.407 0.408 0.410 0.409 
6 0.410 0.409 0.409 0.410 0.411 0.410 
Statistical efficiencies of analysis that use only data from study B relative to analyses 
that include prior data from study A with beta = 0.41(HR=1.5) 
Study A/B 1 2 3 4 5 
2 0.72 0.85 0.90 0.92 0.93 
3 0.65 0.80 0.86 0.89 0.91 
4 0.61 0.77 0.84 0.88 0.90 
5 0.59 0.75 0.83 0.86 0.89 
6 0.58 0.74 0.82 0.85 0.88 
Average estimates from 500 simulations with beta = 0.70 (HR=2) 
Study A/B 0 1 2 3 4 5 
2 0.708 0.709 0.705 0.707 0.704 0.705 
3 0.699 0.707 0.704 0.706 0.704 0.704 
4 0.698 0.706 0.704 0.705 0.704 0.704 
5 0.700 0.706 0.705 0.706 0.704 0.704 
6 0.698 0.705 0.704 0.705 0.703 0.703 
Statistical efficiencies of analysis that use only data from study B relative to analyses 
that include prior data from study A with beta = 0.70 (HR=2) 
Study A/B 1 2 3 4 5 
2 0.72 0.86 0.91 0.93 0.94 
3 0.65 0.81 0.87 0.90 0.92 
4 0.62 0.78 0.85 0.88 0.91 
5 0.60 0.76 0.84 0.87 0.90 
6 0.58 0.75 0.83 0.86 0.89 
 
